Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
Journal of Crohn'S & Colitis
|
March 23, 2019
Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers
Huanyu Zhou, Li Xi, Daniel Ziemek, et al.
Lancet (London, England)
|
May 22, 2017
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
Séverine Vermeire, William J Sandborn, Silvio Danese, et al.
Lancet (London, England)
|
March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.
Gut
|
October 7, 2017
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study
William J Sandborn, Scott D Lee, Dino Tarabar, et al.
Intestinal Research
|
February 5, 2020
Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study
Masayuki Saruta, Dong Il Park, Young-Ho Kim, et al.
Journal of Crohn'S & Colitis
|
September 30, 2017
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study
Geert D'Haens, Séverine Vermeire, Harald Vogelsang, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
Journal of Crohn'S & Colitis
|
March 23, 2019
Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers
Huanyu Zhou, Li Xi, Daniel Ziemek, et al.
Lancet (London, England)
|
May 22, 2017
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
Séverine Vermeire, William J Sandborn, Silvio Danese, et al.
Lancet (London, England)
|
March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.
Gut
|
October 7, 2017
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study
William J Sandborn, Scott D Lee, Dino Tarabar, et al.
Intestinal Research
|
February 5, 2020
Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study
Masayuki Saruta, Dong Il Park, Young-Ho Kim, et al.
Journal of Crohn'S & Colitis
|
September 30, 2017
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study
Geert D'Haens, Séverine Vermeire, Harald Vogelsang, et al.
Page
of 3